反応 #68047
ord-473148dd016b4c6ba71b60824cefb0a1
反応方程式
反応物
試薬
反応条件
後処理
- 1workup.ADDITIONwas added
- 2その他The solvent was removed under reduced pressure, and aqueous saturated sodium hydrogen carbonate solution and chloroform
- 3workup.ADDITIONwere added
- 4その他The organic layer was separated
- 5抽出the aqueous layer was extracted with chloroform
- 6洗浄washed with aqueous saturated sodium chloride solution
- 7乾燥dried over anhydrous magnesium sulfate
- 8その他the solvent was removed under reduced pressure
- 9その他The residue thus obtained
- 10その他was purified by silica gel column chromatography [eluent; chloroform:methanol=10:1]
実験手順
To 2 mL of a chloroform solution containing 0.25 g of methyl 1-(2-(4-((tert-butoxycarbonyl)(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-7-methoxy-2-oxo-1,2-dihydroquinoline-4-carboxylate, 2 mL of trifluoroacetic acid was added and stirred for 16 hours. The solvent was removed under reduced pressure, and aqueous saturated sodium hydrogen carbonate solution and chloroform were added. The organic layer was separated, and the aqueous layer was extracted with chloroform. The organic layer and extracts were combined, washed with aqueous saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The residue thus obtained was purified by silica gel column chromatography [eluent; chloroform:methanol=10:1] to give 0.12 g of methyl 1-(2-(4-((2,3-dihydro-1,4-benzodioxin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-7-methoxy-2-oxo-1,2-dihydroquinoline-4-carboxylate as a white solid.